TSX Movers: Valeant, Gold Stocks, Theratechnologies

The transcript covers Walgreens' positive outlook on its partnership with Valeant, highlighting satisfaction with Valeant's dermatology business. It also discusses the rise in gold prices as investors seek a safe haven amid global market volatility, suggesting a potential bull run. Lastly, it addresses Theratechnologies' lowered sales forecast for Egrifta, following Quebec's decision not to reimburse the drug.

What did Walgreens express about its partnership with Valeant?

What trend is observed in gold trading according to the text?

What are the implications of the Fed's rate hike odds mentioned in the text?

What recent action did Theratechnologies take regarding its sales forecasts?

What was the projected sales figure for egrifta after the forecast adjustment?